Bespak Expands Manufacturing Capacity For Climate-Friendly Inhalers
DevPro And Bespak Complete Feasibility Study For New Albuterol Inhaler
Bespak And MEU Collaborate To Accelerate Climate-Friendly Inhaler Trials
Bespak And H&T Presspart Partner On Low GWP Propellants For PMDIS
HOLMES CHAPEL, UK / ACCESSWIRE / April 2, 2024 / Bespak today announced the completion of the transaction to separate Recipharm's former Advanced Delivery Systems Business Unit from the Recipharm Group to form a new standalone company. Both Bespak and Recipharm are backed by EQT Private Equity. The spin-out has created a leading global contract development and manufacturing organisation (CDMO) focused on drug-device combination products and drug delivery devices for pulmonary and nasal inhalation.
Recipharm, Medspray, Resyca License Soft Mist Tech For Nasal Drug Delivery
Bespak says the availability of the autoinjector version of UCB’s Cimzia on the UK National Health Service (NHS) is a validation of its delivery technology.
Bespak has launched an auto-injector designed to deliver higher viscosity drug formulations.